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Summary 1 
The newly isolated strain Streptomyces sp RSP9 produces two 2 
thiopeptides; one of them is methylsulfomycin I, which shows potent 3 
antibiotic activity against several Gram-positive bacteria such as Micrococcus 4 
luteus and Staphylococcus aureus. The other is a new thiopeptide named 5 
radamycin. In the present work, this compound was purified and tested 6 
against several microorganisms and no antibiotic activity was detected in the 7 
assays. However, it does have a very strong capacity as an inducer of the 8 
tipA promoter, and indeed is the first reported molecule with tipA promoter 9 
induction capacity without detectable antibiotic activity. Induction of the tipA 10 
promoter also occurs with methylsulfomycin I. 11 
 12 
13 
 4 
Introduction 1 
Cyclic thiopeptide antibiotics such as promoinducin, promothiocin, 2 
sulfomycin, thiopeptin, thiostrepton etc, are composed of oxalazole and/or 3 
thiazole rings with modified amino acids and a linear peptide containing 4 
dehydroalanines 1). These antibiotics are active against Gram-positive bacteria 5 
and their mechanism of action is not well understood. The one most studied, 6 
thiostrepton, acts by inhibiting translation through its binding to the large 7 
subunit of the prokaryotic ribosome. Resistance to thiostrepton is generated 8 
by a methylase and has been an important selection marker in Streptomyces 9 
cloning vectors (compiled in 2)). Most of these antibiotics induce the 10 
expression of the tipA promoter, isolated from Streptomyces lividans, which 11 
has been used to develop usefull expression systems in these microorganisms 12 
3). Promoter induction ”in vivo” has also been used to isolate new 13 
thiopeptides such as geninthiocin, promothiocin and promoinducin4-6). 14 
Thompson's group has reported the formation of irreversible thiopeptide-15 
antibiotic-protein complexes with the TipAS protein and have suggested that 16 
the minimal motif for TipA recognition is the linear peptide that extends the 17 
thiazoles and oxazoles attached to positions 4 or 5 of the pyridyl group 1). 18 
Although the main use of these antibiotics has been as growth 19 
promotants for animals, 7; 8), they have lately attracted the interest of 20 
researchers and pharmaceutical companies as new tools against methicilin-21 
resistant (MRSA) and/or vancomycin-resistant (VRE) Staphylococcus aureus  22 
infections 9). 23 
 5 
Here we describe the isolation and identification of strain Streptomyces 1 
sp RSP9, its fermentation conditions, the isolation and biological activities of 2 
two thiopeptide compounds produced by this strain, and the capacity for tipA 3 
promoter induction by these compounds. One of the molecules is the recently 4 
described antibiotic methylsulfomycin I 9) and the other is a novel that we 5 
have named radamycin (Fig. 1). The structure of both compounds was 6 
determined and that of radamycin is described in the accompanying paper 10). 7 
 8 
9 
 6 
MATERIALS AND METHODS  1 
Microorganisms and Media  2 
 Streptomyces sp RSP9 spores were harvested from R2YE or from SFM 3 
solid media 2) and used to inoculate (106 spores/ml) different liquid media to 4 
study antibiotic production. Fermentations were carried out in different 5 
modifications of medium YES (1% Yeast extract, 10,3% sucrose [pH7.2] 6 
supplemented with 0.5% xylose and 5 mM MgCl2 ). Cultures were incubated at 7 
28ºC for 4-7 days on a rotary shaker at 200 rpm. Other media, such as SPG 8 
11) or Trypticase Soy Broth (TSB) 2), were used in some experiments. 9 
Normally, three baffled 100 ml flasks containing 10 ml of media were used.  10 
Taxonomy 11 
Streptomyces sp RSP9 was identified by morphological, physiological 12 
and molecular characterisation methods. Total DNA was obtained from cells 13 
grown on YES for 24 h 12) and the 16S rDNA was amplified using the Expand 14 
High Fidelity PCR System (Roche) and the primers 27f 15 
(5’AGAGTTTGATCCTGGCTCAG 3’) and 1522r (5’ AAGGAGGTGATCCANCCRCA 16 
3’), which amplified almost the complete gene 13). f, indicates the forward 17 
strand and r the reverse one. N indicates any nucleotide and R indicates A or 18 
G.  19 
 Sequencing was done using the following primers: 20 
27f (5’ AGAGTTTGATCCTGGCTCAG 3’); 339r (5’ ACTGCTGCCTCCCGTAGGAG 21 
3’) 22 
 7 
358f (5’ CTCCTACGGGAGGCAGCAGT 3’); 519f (5’ CAGCAGCCGCGGTAATAC 1 
3’) 2 
849f (5’ GCCTGGGGAGTACGGCCGCA 3’); 1112f (5’ 3 
AGTCCCGCAACGAGCGCAAC 3’) 4 
1150f (5’ GGGGATGACGTCAAGTCATCA 3’);1500r(5’ 5 
AAGGAGGTGATCCAGCCGCA 3’) 6 
Antibiotic production  7 
The time-course of antibiotic production was studied in duplicate in 8 
500 ml Erlenmeyer flasks (baffled) with 100 ml of YES medium. These flasks 9 
were inoculated with 1 ml of 24 h-old culture in the same media and 10 
incubated at 28ºC. Samples (5 or 1.5 ml) were collected every 24 h up to 10 11 
days and the antibiotic activity present in culture supernatants and cells was 12 
tested. The antibiotic present in the cells was extracted by adding acetone 13 
and vortexing for 30 sec, followed by centrifugation at 10,000xg for 10 min. 14 
Overall growth was monitored as dry weight (cells were washed twice with 15 
10mM phosphate buffer, pH 6,8 and dried at 50 ºC for 72 h). 16 
 For antibiotic purification, three liters of YES medium supplemented 17 
with 0,5% xylose and 2mM MgCl2 were inoculated with 106 spores/ml of 18 
Streptomyces sp RSP9 and aliquoted into 500 ml four baffled Erlenmeyer 19 
flasks at 150 ml each. Cultures were incubated for four days in a shaker at 20 
200 rpm and the whole cultures were mixed with 3 litres of n-butanol and 21 
vortexed for 30 sec several times. Phases were separated by centrifugation 22 
at 10,000xg for 10 min and the organic layer was harvested and 23 
 8 
concentrated under reduced pressure, giving an oily brownish residue. The 1 
residue was dissolved in 500 ml of a mixture 10% aqueous NaCl-MeOH 1:1 2 
and the hydro-alcoholic layer was extracted twice with 500 ml of CHCl3 and 3 
the active CHCl3 extracts were concentrated and chromatographed on silica 4 
gel. 5 
Analytical procedure 6 
 Analytical TLC was accomplished on pre-coated silica gel 60 F254 7 
plates (0.2 mm thick, 20x20 cm, Merck) and the spots were detected under 8 
UV light (254 nm). Silica gel 60 (70-230 mesh, Merck) and Lichroprep RP-18 9 
(40-63 mm, Merck) were used for column chromatography. HPLC analysis 10 
was performed on a Waters 991 apparatus with a photodiode-array detector 11 
and a Rheodyne injector, using a Resolve C18 analytical radial pack cartridge 12 
(10µ, Waters Chromatography), using CH3CN-H2O, 96:4, as a mobile phase 13 
at a flow rate of 2.0 ml/min and detection at 250 nm.  14 
Biological Assays 15 
Antimicrobial activity against different bacteria and yeasts grown on 16 
YEPD-agar 14) was studied in diffusion assays on agar plates. Wells of 0.5 cm 17 
diameter were bored on plates inoculated with the different microorganisms 18 
and several quantities of supernatant or pure antibiotic were assayed. 19 
Activity was observed and measured after 24 or 48 h of incubation at 28oC.  20 
tipA promoter (tipAp) induction by the purified thiopeptide molecules 21 
was studied in S. lividans transformed with the multicopy plasmid pAK114 or 22 
with pGG016, a single-copy integrative plasmid. In pAK114,  thiostrepton-23 
 9 
inducible tipAp controls the expression of a kanamycin resistance gene 15), 1 
and in pGG016 tipAp controls the expression of a truncated xylanase gene 2 
derived from the xysA gene from S. halstedii JM8 16; 17). In this work, pGG016 3 
was constructed by cloning the DNA fragment of the xysA gene (xysA∆), 4 
which encodes the catalytic domain of xylanase under the control of the tipA 5 
promoter, into the integrative plasmid vector pIJ8600 18). 6 
S.lividans transformed with pAK114 was used to study the tipA 7 
induction effect in culture supernatants or pure compounds (5 to 30 ng). 8 
Spores of this strain were inoculated as a lawn onto R2YE plates containing 9 
15 µg/ml neomycin. Different quantities of filter-sterilized supernatant or 10 
purified compounds were deposited in wells and the plates were incubated at 11 
28ºC.The induction capacity of total supernatant or pure compounds was 12 
detected as growth halos around the wells. Halo size depended on the 13 
kanamycin concentration and on the concentration and effectiveness of the 14 
inducer. 15 
tipA induction on liquid media was studied by inoculating spores of S. 16 
lividans transformed with pGG016 in YES medium supplemented with 17 
different amounts (2 to 10 µg/ml) of the purified compounds. 18 
Cultures with the same amounts of thiostrepton were used as controls 19 
of induction. Samples of the induced supernatants were collected at different 20 
times and analyzed by denaturing polyacrylamide gel electrophoresis(SDS-21 
PAGE). The truncated ΔXys1 produced was detected after Coomassie Blue 22 
staining as a band of 30 kDa or by Western blot with anti-Xys1 antibodies 16).  23 
 10 
1 
 11 
RESULTS AND DISCUSSION 1 
 2 
Streptomyces sp RSP9 isolation and taxonomy 3 
The strain Streptomyces sp RSP9 was isolated in a screening procedure 4 
for Streptomyces protease-producing strains (González Holgado and 5 
Santamaría, unpublished). Morphologically, this strain grows abundantly in 6 
complex and synthetic media. The spores are green-grey on R2YE and SFM 7 
media. Mycelia (back side of the plates) are yellowish-brown. This strain does 8 
not liquefy agar, indicating undetectable agarase activity, but does produce 9 
several extracellular enzymes such as amylases, cellulases, xylanases and 10 
proteases. A study of these enzymes is currently underway. 11 
 Streptomyces sp RSP9 was identified on the basis of its 16S rDNA 12 
sequence. Comparison of the sequence obtained with those found in the 13 
databases showed 99,87% identity to S. griseus and Streptomyces sp 14 
AA8321.1 (only two nucleotides out of 1518 are different). Thus, we 15 
tentatively consider Streptomyces sp RSP9 as a new S. griseus sub-species.  16 
Antibiotic production 17 
Further characterization permitted us to observe that Streptomyces sp 18 
RSP9 culture supernatants displayed strong antibiotic activity against several 19 
Gram+ microorganisms such as Micrococcus luteus, Bacillus subtilis, 20 
Brevibacterium lactofermentum and Staphylococcus aureus, but no activity 21 
was detected against Mycobacterium smegmatis, Escherichia coli, Sarcina 22 
lutea, Pseudomonas aeruginosa, Saccharomyces cerevisiae or animal cells . 23 
 12 
The results of the experiments described here were obtained with M. luteus 1 
as the test strain.  2 
Antibiotic production was studied in several complex media, YES giving 3 
the best results. Other media, such as SPG, also gave an acceptable 4 
production (57.14% of the production obtained in YES). In order to optimize 5 
the production in YES medium, we studied the effect of the addition of 6 
glucose or xylose. Concentrations ranging from 0 to 5% of each 7 
monosaccharide were assayed on YES medium with and without 5mM MgCl2 8 
and production after 96 h was evaluated in plate diffusion bioassays. A clear 9 
positive effect was observed when increasing concentrations of xylose were 10 
added to YES without MgCl2. However, the best production was obtained in 11 
YES with MgCl2 supplemented with xylose. In this medium, production was 12 
very similar at all the concentrations of xylose used, although it was slightly 13 
higher with 5% xylose, Fig. 2A. With glucose, the best production was 14 
obtained at 1%, slightly lower than that obtained with xylose (data not 15 
shown). From this experiment onwards, all fermentations were carried out in 16 
YES supplemented with 0.5% xylose and MgCl2.  17 
The effect of different concentrations of MgCl2 (0 to 100 mM) was 18 
evaluated in YES media supplemented with 0.5% xylose. The best production 19 
was obtained on media supplemented with 2 mM MgCl2 Fig. 2B. All 20 
successive fermentations were thus carried out in modified YES media (1% 21 
Yeast extract, 10.3% sucrose [pH 7,2] supplemented with 0.5 % xylose and 22 
2 mM MgCl2).  23 
 13 
A fermentation time-course study was performed in 500-ml Erlenmeyer 1 
flasks as indicated in Materials and Methods and the antibiotic present in the 2 
supernatant and in the cells was evaluated in bioassays. After 24 h, the 3 
presence of antibiotic was detected in both fractions, and was found to be 4 
more abundant in the supernatant (58%) than in cells (42%). Maximum 5 
production was observed at 72 h, after which it reached a plateau and 6 
remained stable for up to 10 days of incubation Fig. 3. Since both 7 
supernatant and cells contained considerable activity, we decided to process 8 
both together for antibiotic purification. 9 
 10 
Antibiotic isolation and Purification 11 
 12 
The procedure used for isolating antibiotic activity is summarized in 13 
Fig. 4. After 96 h, the culture (3 liters) was mixed with 3 liters of n-butanol. 14 
After centrifugation the organic layer was harvested and concentrated under 15 
reduced pressure, giving a brownish oily residue (3.0 g). The residue was 16 
dissolved in 500 ml of a mixture 10% aqueous NaCl-MeOH, 1:1, and the 17 
hydro-alcoholic layer was extracted twice with 500 ml of CHCl3. The active 18 
CHCl3 extracts were concentrated to yield 1.1 g of oil. The extract was 19 
chromatographed on silica gel using a VFC (Vacuum Flash Chromatography) 20 
system with CHCl3-MeOH as the eluting solvent. Fractions containing 21 
compound 1 (60 mg) and compound 2 (55 mg) were eluted with CHCl3-22 
MeOH, 97:3, in different fractions. The final purification of both compounds 23 
 14 
was carried out by C18 reversed phase chromatography, affording 28 mg of 1 
pure compound 1 eluted with MeOH-H2O, 85:15, and 23 mg of compound 2 2 
eluted with MeOH-H2O, 70:30. The purity of each preparation was confirmed 3 
by TLC visualized with vanillin in concentrated H2SO4 and by analytical HPLC 4 
with a photo-diode array detector.  5 
Structural elucidation of both compounds was obtained; the compound 1 6 
corresponding to radamycin is described in the accompanying paper. The 7 
structure of compound 2 corresponds to methylsulfomycin I, an antibiotic 8 
recently patented and published 9).  9 
 10 
 Biological properties 11 
 12 
 After purification, we tested the antibiotic activity of both pure 13 
compounds against M. luteus. While methylsulfomycin I exhibited powerful 14 
inhibitory activity, we were unable to observe any effect caused by 15 
radamycin. This suggests that the antibiotic activity detected in supernatants 16 
and cells is due to methylsulfomycin I alone, although inactivation of an active 17 
radamycin precursor during the purification procedure cannot be ruled out. 18 
Radamycin itself appeared to be fairly stable since, even after 6 months in a 19 
refrigerator, it showed no signs of modification in its HPLC pattern. We 20 
therefore consider radamycin to be a final, stable product rather than an 21 
intermediate compound. A mutant strain defective in methylsulfomycin I 22 
production would answer this question. 23 
 15 
 1 
Antimicrobial activity was also tested against 30 different clinical 2 
isolates of Staphylococcus aureus. Again, methylsulfomycin I showed a strong 3 
inhibitory effect against all the isolates in plate diffusion assays. Amounts as 4 
low as 0.3 µg/well were enough to give halos of 1.55 cm. However, none of 5 
the radamycin samples (25 ng to 3 µg per well) inhibited S. aureus growth. 6 
 In another set of experiments S. lividans was found to be sensitive to 7 
methylsulfomycin I but not to radamycin. However, it is worth noting that S. 8 
lividans sensitivity decays with time and that the mycelia eventually overgrow 9 
the area of initial inhibition. In addition, the external border of the inhibition 10 
area (in the transition to the fully-grown mycelium) showed accelerated aerial 11 
mycelium formation and sporulation. This effect and the inhibition of growth 12 
were more clearly seen when supernatants rather than pure compounds were 13 
used for the plate diffusion assays. This suggests that better solubility, 14 
higher stability or some kind of synergism might occur in the supernatants 15 
that are absent in the purified compounds. With radamycin, a slightly 16 
increased acceleration in sporulation was observed.  17 
A known biological property of many thiopeptide molecules (first seen 18 
with thiostrepton) is their ability to induce the production of several proteins 19 
(thiostrepton induced proteins, Tip) by Streptomyces lividans and other 20 
strains apparently unable to produce their own thiopeptides. The tipA gene 21 
corresponding to one of these proteins -TipA -has been cloned and 22 
characterized. TipA is a transcription factor that, upon binding the 23 
 16 
thiopeptide, activates its own expression and probably that of other tip 1 
genes. The actual function of this thiopeptide-sensing system is unknown, 2 
but could be linked to low resistance levels to the cognate thiopeptide 3 
antibiotics 19). 4 
We tested the ability of both methylsulfomycin I and radamycin to 5 
induce the tipA promoter (tipAp) in S. lividans. Two reporter systems were 6 
used. First, S. lividans was transformed with pAK114, a derivative of the 7 
multicopy vector pIJ486, where the tipA promoter drives the expression of 8 
the Tn5 neomycin resistance gene 15). 5 ng of methylsulfomycin I or 9 
radamycin were able to activate the tipA promoter and allowed the pAK114 10 
transformants to grow on plates containing 15 µg of neomycin (Fig. 5A). 11 
Growth, measured as halos around wells where the molecules had been 12 
deposited was clearly dose-dependent (Fig. 5A). 13 
In another set of experiments, we used the xysA∆ gene of a truncated 14 
secreted xylanase (Xys1∆) from Streptomyces hastedii JM8 17) as reporter. 15 
The xysA∆ gene was cloned downstream from the tipA promoter in the single 16 
copy E. coli-Streptomyces shuttle vector pIJ8600 18) to give plasmid 17 
pGG016. This construction integrates at the ΦC31 attachment site in the 18 
chromosome. We made up duplicated master liquid cultures (50 ml of YES 19 
medium with 1% Glucose, 5mM MgCl2) of S. lividans transformants carrying 20 
either pIJ8600 (empty vector) or pGG016 (xysA∆). After 18 hours of 21 
growth, the cultures were split into four aliquots. Three of them were 22 
supplemented with 2.5 or 10 µg/ml of thiostrepton, methylsulfomycin I or 23 
 17 
radamycin. The fourth aliquot was left unsupplemented as an uninduced 1 
control. Incubation was continued and 1 ml samples were withdrawn at 2 
different times after induction and analyzed to detect the xylanase protein 3 
Xys1. Xys1 was detected by Western-blot using anti-Xys1 antibodies. All 4 
three compounds were able to induce the tipA promoter (Fig 5B). By the 5 
intensity of the protein band induced by 10µg/ml of radamycin  that 6 
radamycin looks more powerful than thiostrepton and methylsulfomycin I. 7 
The ability of radamycin to induce the tipA promoter in the absence of 8 
detectable antibiotic activity would permit the construction of inducible tipAp 9 
vectors lacking a thiostrepton resistance gene, tsr. On the other hand, the 10 
lack of antibiotic activity in radamycin would allow its use as a tipAp inducer 11 
for the industrial scale production of proteins without the need for antibiotic 12 
addition with a view of preventing the selection of thiopeptide antibiotic-13 
resistant strains. 14 
 The fact that radamycin lacks antibiotic activity while at the same time 15 
preserving tipA induction capacity may allow its use in the study of structure-16 
function relationships in thiopeptide antibiotics. 17 
 18 
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Figure legends 1 
Fig. 1 Structure of radamycin. 2 
 3 
Fig. 2. A) Antibiotic production in the presence of different quantities of 4 
xylose. 5 
  YES without MgCl2.  YES containing 5mM Mg Cl2.  6 
Fig. 2. B) Antibiotic production  in the presence of different amounts of 7 
MgCl2. 8 
 9 
Figure 3. Time-course of antibiotic production in YES.  Growth,  antibiotic in 10 
the supernatant,  antibiotic in the cells 11 
 12 
Figure 4. Procedure for the isolation of radamycin. 13 
 14 
Figure 5. A) Expression of the aphII (neo) gene under the control of tipAp. fdt 15 
is a transcriptional terminator; tsr is a gene encoding resistance to 16 
thiostrepton. The numbers indicate the amount (in ng) of methylsulfomycin I 17 
or radamycin deposited in each well . 18 
B) Expression of the xysA gene under the control of tipAp. λto and fdt are 19 
transcriptional terminators. amr, apramycin resistance; int ΦC31 integrase. 20 
The numbers indicate, in µg/ml, the amounts of thiostrepton (Thio); 21 
methylsulfomycin (Ms) or Radamycin(Rd) added to the cultures. pGG016 is a 22 
pIJ860018) derivative. 23 
 23 
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Fig. 1: González Holgado et al. 
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Fig.1. Structures of radamycin (1) and  methylsulfomycin (2)
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Fig.  2: González Holgado et al. 
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Fig. 3: González Holgado et al. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: González Holgado et al. 
 
 
 Extracted with n-BuOH 
 Partition 
 CHCl3-NaCl (10%)-MeOH  2:1:1 
Organic Extract  3.0 g 
Chloroform extract  1.1 g 
Whole broth (3 liters) 
 VFC on silica gel 
 Eluted with CHCl3-MeOH 97:3 
RP-18 column chromatography 
Eluted with MeOH-H2O  85:15 
Compound 1 (28 mg) 
 
Fractions  containing 1 Fractions  containing 2 
RP-18 column chromatography 
Eluted with MeOH-H2O  7:3 
Compound 2 (23 mg) 
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Fig. 5. González Holgado et al.
